The U.S. Food and Drug Administration (FDA) has recently approved a new non-surgical treatment option for patients with prostate cancer. The non-invasive method is called High-Intensity Focused Ultrasound (HIFU) therapy and Dr. David Samadi explains more about in the video above.
HIFU is used to destroy diseased prostate tissue without harming the surrounding tissue and was approved by the FDA after 10 years of use Europe and Canada.
“For selected patients with low-risk prostate cancer and a small prostate, this can actually play a role. There is a transducer in the rectum, and with a general anesthesia, you basically use a high focus ultrasound energy and you can actually burn the cancer cells,” said Samadi in the video.
Dr. Samadi said data from HIFU in Europe shows effective results among selected prostate cancer patients.
HIFU is meant for low-risk patients in stage T-1 or T-2 of prostate cancer confined to the gland. The treatment consists of ultrasound waves precisely directed at the tumor via a computer controlled rectal probe to destroy the prostate cancer cells. The process can be repeated if necessary. Although side effects are lower than from surgery or radiation, HIFU may cause incontinence or erectile dysfunction.
Maple Leaf HIFU is the first provider of this technology and treatment in North America.
Prostate Cancer News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.